Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy

Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy

Perhaps the greatest limitation for the continually advancing developments in cancer immunotherapy remains the immunosuppressive tumor microenvironment (TME). The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) axis is an emerging immunotherapy target, with the resulting type I...

Full description

Bibliographic Details
Main Authors: Jordan D. Lewicky, Alexandrine L. Martel, Nya L. Fraleigh, Emilie Picard, Leila Mousavifar, Arnaldo Nakamura, Francisco Diaz-Mitoma, René Roy, Hoang-Thanh Le
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Pharmaceutics
Subjects:
cancer immunotherapy
immunomodulation
cGAS-STING
DNA damage response
low dose cytarabine
mannosylated cationic liposome
Online Access:https://www.mdpi.com/1999-4923/14/12/2710

Internet

https://www.mdpi.com/1999-4923/14/12/2710

Similar Items